The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Slack Technologies' reference price was set at $26 per share, the New York Stock Exchange announced Wednesday evening.Technologyread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
With the Federal Reserve deciding not to cut interest rates but leaving the door open for future cuts, experts are split on what comes next.Trading Nationread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social CapitalTechnologyread more
Investors need to be cautious because the economy will get hurt the longer the trade war drags on, Jim Cramer says.Mad Money with Jim Cramerread more
Oracle found revenue growth from cloud applications in its fiscal fourth quarter, which helped it surpass analysts' expectations.Technologyread more
Pharmaceutical companies are overcharging for vaccines, driving costs so prohibitively high and threatening international vaccination programs, according to a report from international aid organization Doctors Without Borders (Medicins Sans Frontieres).
The cost of vaccinating a child against a portfolio of serious diseases—measles, whooping cough, tuberculosis and others—was less than 70 cents in 2001. The cost of the program was $45 in 2014, according to an article on the report by the BBC. One reason is that new vaccines have been added to the program: the pneumococcal vaccine alone accounts for almost 50 percent of the current total price. Pneumococcal disease kills one million children a year.
But Doctors Without Borders staffers say the main problem is that pharmaceutical companies are charging needlessly high prices, and that the vaccine industry is too secretive about pricing information. In some extreme cases, developing countries such as Morocco and Tunisia are paying more for the pneumococcal vaccine than far wealthier France does. MSF wants Pfizer and GlaxoSmithKline to reduce the price of the pneumococcal vaccine to $5, about $1 less than a version that Indian drugmaker Serum Institute plans to release next year.
Pfizer said in a statement that the cost of its vaccines reflects what it costs to develop them, and GlaxoSmithKline said it sells its vaccines to poorer countries at a "substantial discount" off its price in wealthier ones.